Stock IMVT IMMUNOVANT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Immunovant, Inc.

Equities

IMVT

US45258J1025

Real-time Estimate Cboe BZX
Other stock markets
 11:21:20 2024-05-23 am EDT 		5-day change 1st Jan Change
29.14 USD -1.44% Intraday chart for Immunovant, Inc. -7.24% -30.69%
Apr. 20 Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing MT
Apr. 20 Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing
MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing
MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target
MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target
MT
Immunovant Awarded U.S. Patent for IMVT-1402
AQ
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing
MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target
MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target
MT
Immunovant Posts Narrower Fiscal Q3 Loss
MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
AQ
North American Morning Briefing : Stock Futures -2-
DJ
North American Morning Briefing : Jobs Report Tops -2-
DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing
MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating
MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial
DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMVT Stock
  4. News Immunovant, Inc.